N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, provides an update on its Covid-19 proof of concept work utilising Nuvec loaded with Coronavirus plasmid.

As announced on 12 August 2020, stage 2 of the proof of concept work was successfully completed with the transfection of HEK (Human Embryonic Kidney) cells of Nuvec loaded with Coronavirus plasmid in vitro. Following the completion of stage 3 of the proof of concept work and a review of the results, the Company is continuing to explore the utility of Nuvec with the Coronavirus plasmid and will progress to an in vivo study in due course.

The Company is in the process of scoping the programme of studies required.

Nigel Theobald, Chief Executive Officer, commented: 'The initial pilot work of stage 3 of the Covid-19 proof of concept work was narrow in its scope and, having reviewed the results, we have taken the decision to move to a full in vivo study to establish an immune response through the production of antibodies. In undertaking the work we aim to demonstrate Nuvec's capabilities both as a potential delivery technology for multiple vaccines as well as for Covid-19 specifically. I look forward to providing further updates in due course.'

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

Contact:

Nigel Theobald

Tel: +44(0)20 3470 0470

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

(C) 2020 Electronic News Publishing, source ENP Newswire